AstraZeneca immunotherapy combo flunks another lung cancer study - MedCity News

AstraZeneca immunotherapy combo flunks another lung cancer study  MedCity News

The company said Wednesday that the pairing of PD-L1 inhibitor Imfinzi and CTLA-4 inhibitor tremelimumab did not prolong overall survival in previously ...



Comments

Popular posts from this blog

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Stage 4 Lung Cancer Life Expectancy

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...